
    
      Primary Objective is to determine the efficacy, as measured by overall response rate on the
      basis of Revised Response Criteria for Malignant Lymphoma, of SyB L-0501 at 120 mg/m^2/day on
      day2 and 3 in combination with rituximab at 375 mg/m^2 on day 1 of each 21-day cycle in
      patients with relapsed/refractory diffuse large B-cell lymphoma.
    
  